ARTICLE | Clinical News
CTAP101: Phase III started
October 1, 2012 7:00 AM UTC
Cytochroma began the first of 2 identical, double-blind, placebo-controlled, U.S. Phase III trials to evaluate 30 and 60 µg oral CTAP101 once daily for 6 months in about 210 patients. The company has ...